615 related articles for article (PubMed ID: 15475459)
1. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the met receptor in mesothelioma.
Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA
Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245
[TBL] [Abstract][Full Text] [Related]
3. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
5. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.
Cai W; Rook SL; Jiang ZY; Takahara N; Aiello LP
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1885-93. PubMed ID: 10845613
[TBL] [Abstract][Full Text] [Related]
7. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
9. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
Xu H; Washington S; Verderame MF; Manni A
Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
[TBL] [Abstract][Full Text] [Related]
10. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor.
Holt RU; Baykov V; Rø TB; Brabrand S; Waage A; Sundan A; Børset M
Haematologica; 2005 Apr; 90(4):479-88. PubMed ID: 15820943
[TBL] [Abstract][Full Text] [Related]
11. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
12. MAP kinase and beta-catenin signaling in HGF induced RPE migration.
Liou GI; Matragoon S; Samuel S; Behzadian MA; Tsai NT; Gu X; Roon P; Hunt DM; Hunt RC; Caldwell RB; Marcus DM
Mol Vis; 2002 Dec; 8():483-93. PubMed ID: 12500177
[TBL] [Abstract][Full Text] [Related]
13. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
[TBL] [Abstract][Full Text] [Related]
14. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
15. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.
Watanabe T; Tsuda M; Makino Y; Ichihara S; Sawa H; Minami A; Mochizuki N; Nagashima K; Tanaka S
Mol Cancer Res; 2006 Jul; 4(7):499-510. PubMed ID: 16849525
[TBL] [Abstract][Full Text] [Related]
16. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
[TBL] [Abstract][Full Text] [Related]
17. Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide.
Tam EM; Runyon ST; Santell L; Quan C; Yao X; Kirchhofer D; Skelton NJ; Lazarus RA
J Mol Biol; 2009 Jan; 385(1):79-90. PubMed ID: 18973760
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1.
Matsushita A; Götze T; Korc M
Cancer Res; 2007 Nov; 67(21):10309-16. PubMed ID: 17974973
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
Yamamoto N; Mammadova G; Song RX; Fukami Y; Sato K
J Cell Sci; 2006 Nov; 119(Pt 22):4623-33. PubMed ID: 17062641
[TBL] [Abstract][Full Text] [Related]
20. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]